Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Molly G. Minze"'
Publikováno v:
Clinical Medicine Insights: Endocrinology and Diabetes, Vol 2013, Iss 6, Pp 15-24 (2013)
Externí odkaz:
https://doaj.org/article/abfa0cbabdc24030844a6bf2d67b2808
Publikováno v:
Global Journal of Obesity, Diabetes and Metabolic Syndrome. 7:009-011
Diabetes remains the leading cause of chronic kidney disease and with its increased prevalence the risk for Diabetic Kidney Disease (DKD) continues to rise and has a significant impact on diabetes morbidity and mortality as well as health care resour
Autor:
Maria Sheridan, Jimmi Hatton Kolpek, Jason H. Karnes, Kara L. Birrer, Christine M. Formea, Rebecca Pulk, Jonathan G. Leung, Janna Afanasjeva, Molly G. Minze, Elias B. Chahine, Chasity M. Shelton, Lamis R. Karaoui, Christopher R. Ensor, Eglis Tellez-Corrales, Christine M. Walko, James C. Lee, Angela Q. Maldonado, Keri C. Anderson, Erin F. Barreto, Jomy M. George, Roseann S. Gammal, Shubha Bhat, Craig J. Beavers, Stephanie A. Flowers, Mary F. Hebert, Kelly E. Caudle, Michael A. Smith, Scott A Soefje, Larisa H. Cavallari, Rena A. Gosser
Publikováno v:
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2:288-302
Publikováno v:
Am J Pharm Educ
Objective. Pharmacy programs have struggled to predict who will be successful in their programs based solely on cognitive skills. The primary objective of this study was to determine which, if any, nonacademic factors are associated with on-time prog
Publikováno v:
Current Diabetes Reviews. 14:509-517
Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new pharmacotherapeutic class for the treatment of Type 2 Diabetes Mellitus (T2DM). Objective To evaluate beneficial effects of the SGLT2 inhibitors on metabolic, cardiovascular, and
Publikováno v:
Expert review of endocrinologymetabolism. 10(6)
Type 2 diabetes effects millions of people yet remains difficult to treat with oral pharmacotherapy. Metformin is the first line recommended therapy, and current guidelines suggest individualized therapy for second line selection. Sodium-glucose co-t
Autor:
Molly G. Minze, Brian K Irons
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Irons BK, Minze MG. Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes Metab Syndr Obes. 2014;7:15–24.There is an error in the text on page 19:“Alpha-glucosidase inhibitors are infrequently used
Autor:
Molly G. Minze, Lisa M. Chastain
Publikováno v:
Therapeutics and Clinical Risk Management
The global burden of type 2 diabetes is estimated to currently affect over 350 million people worldwide and is anticipated to continue increasing over the next 20 years. Current treatment guidelines recommend the choice of pharmacotherapy based upon
Objective. To evaluate the pharmacokinetic, safety, and effectiveness data of dosing low-molecular-weight heparins (LMWHs) for prophylaxis of venous thromboembolic events (VTEs) in obese people. Data Sources. A PubMed search (1966 to September 2015)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12c094a4664cbdd59f4aae1be40958f7
https://europepmc.org/articles/PMC5998535/
https://europepmc.org/articles/PMC5998535/
Autor:
Molly G. Minze, Brian K Irons
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Metformin is considered an initial drug of choice for type 2 diabetes mellitus by leading recommendations. When contraindications to its use exist or patients cannot tolerate it due to adverse effects, clinicians have a variety of other classes of ag